1. Scrip
  2. >>Business

Can Dr Reddy’s Carve Into Crowded Indian Avastin Biosimilar Market?

 
• By Anju Ghangurde

Dr Reddy’s debuts biosimilar bevacizumab in India but can the significant price differential for one strength of the product help it gnaw into a competitive market?

Leadership
Dr Reddy's Launches Cut-Price Biosimilar Avastin In India • Source: Shutterstock

Dr. Reddy's Laboratories Ltd. has introduced its biosimilar version of Roche’s anticancer Avastin (bevacizumab) in India, trailing peers into a crowded segment which has recently seen price regulation.

Dr Reddy’s biosimilar bevacizumab, marketed as Versavo, goes up against some formidable rivals, with over half a dozen firms including Mylan NV, Biocon Ltd., Intas Pharmaceuticals Ltd., Reliance Life Sciences, Hetero Drugs Ltd. and Zydus Cadila already selling other Avastin biosimilars on the Indian market

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics, Biosimilars

 
• By Dave Wallace

A free trade agreement between the UK and India could offer “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments.